Aker Christopher Ray
Sr. VP & General Counsel at Regulus Therapeutics Inc.
- Sold, on record
- $86k
- Dollars the filings state
- Form 4 sales
- 15
- Latest Jan 14, 2025
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Regulus Therapeutics Inc.Sr. VP & General Counsel
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Regulus Therapeutics Inc.Plan not statedFeb 18, 2020 2020
Sold 888 shares at $0.83 ($737)
Aker Christopher Ray, Sr. VP & General Counsel
Sold 3% of holdings ($24k position)28,419 shares left0.4x usual sizeFiling
- 2 Form 4 sale Regulus Therapeutics Inc.Plan not statedMay 15, 2020 +87 days
Sold 909 shares at $0.63 ($573)
Aker Christopher Ray, Sr. VP & General Counsel
Sold 3.2% of holdings ($18k position)27,510 shares left0.4x usual sizeFiling
- 3 Form 4 sale Regulus Therapeutics Inc.Plan not statedAug 14, 2020 +91 days
Sold 872 shares at $0.61 ($532)
Aker Christopher Ray, Sr. VP & General Counsel
Sold 3.2% of holdings ($17k position)26,638 shares left0.4x usual sizeFiling
- 4 Form 4 sale Regulus Therapeutics Inc.Plan not statedNov 16, 2020 +94 days
Sold 876 shares at $0.52 ($456)
Aker Christopher Ray, Sr. VP & General Counsel
Sold 3.3% of holdings ($14k position)25,762 shares left0.6x usual sizeFiling
- 5 Form 4 sale Regulus Therapeutics Inc.Plan not statedFeb 16, 2021 +92 days
Sold 828 shares at $1.72 ($1k)
Aker Christopher Ray, Sr. VP & General Counsel
Sold 1.9% of holdings ($75k position)42,614 shares left0.9x usual sizeFiling
- 6 Form 4 sale Regulus Therapeutics Inc.Plan not statedMay 17, 2021 +90 days
Sold 860 shares at $0.89 ($765)
Aker Christopher Ray, Sr. VP & General Counsel
Sold 2% of holdings ($38k position)41,754 shares left1x usual sizeFiling
- 7 Form 4 sale Regulus Therapeutics Inc.UnusualJan 18, 2024 +976 days
Sold 5,468 shares at $1.19 ($7k)
Aker Christopher Ray, Sr. VP & General Counsel
No 10b5-1 planSold 35.2% of holdings ($18k position)10,056 shares leftFirst sale on recordFiling
- 8 Form 4 sale Regulus Therapeutics Inc.RoutineJan 14, 2025 +362 days
Sold 43,635 shares at $1.26 ($55k)
Aker Christopher Ray, Sr. VP & General Counsel
10b5-1 planSold 46.8% of holdings ($117k position)49,546 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (15)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 14, 2025 | Jan 15, 2025 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 43,635 | $55k | 46.8% | Routine | SEC |
| Jan 18, 2024 | Jan 18, 2024 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 5,468 | $7k | 35.2% | Unusual | SEC |
| May 17, 2021 | May 17, 2021 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 860 | $765 | 2.0% | Plan not stated | SEC |
| Feb 16, 2021 | Feb 17, 2021 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 828 | $1k | 1.9% | Plan not stated | SEC |
| Nov 16, 2020 | Nov 18, 2020 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 876 | $456 | 3.3% | Plan not stated | SEC |
| Aug 14, 2020 | Aug 17, 2020 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 872 | $532 | 3.2% | Plan not stated | SEC |
| May 15, 2020 | May 18, 2020 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 909 | $573 | 3.2% | Plan not stated | SEC |
| Feb 18, 2020 | Feb 19, 2020 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 888 | $737 | 3.0% | Plan not stated | SEC |
| Jan 2, 2020 | Jan 3, 2020 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 2,239 | $2k | 7.1% | Plan not stated | SEC |
| Nov 14, 2019 | Nov 15, 2019 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 833 | $533 | 2.6% | Plan not stated | SEC |
| Oct 1, 2019 | Oct 2, 2019 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 2,346 | $2k | 6.8% | Plan not stated | SEC |
| Aug 15, 2019 | Aug 16, 2019 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 899 | $494 | 2.5% | Plan not stated | SEC |
| Jul 1, 2019 | Jul 2, 2019 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 2,225 | $3k | 5.9% | Plan not stated | SEC |
| May 15, 2019 | May 16, 2019 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 6,950 | $10k | 10.5% | Plan not stated | SEC |
| Apr 1, 2019 | Apr 3, 2019 | Regulus Therapeutics Inc. | Sr. VP & General Counsel | Form 4 sale | 2,710 | $3k | 30.1% | Unusual | SEC |